<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5872">
  <stage>Registered</stage>
  <submitdate>9/05/2016</submitdate>
  <approvaldate>9/05/2016</approvaldate>
  <nctid>NCT02770040</nctid>
  <trial_identification>
    <studytitle>Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis</studytitle>
    <scientifictitle>PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis - A Randomised Controlled Trial</scientifictitle>
    <utrn />
    <trialacronym>PREDICT-UC</trialacronym>
    <secondaryid>HREC/14/Austin/595</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ulcerative Colitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Infliximab

Active Comparator: Intensified Infliximab Induction - Infliximab 10mg/kg at Week 0 and Week 1

Active Comparator: Accelerated Infliximab Induction - Infliximab 5mg/kg at Week 0, Week 1 and Week 3

Active Comparator: Standard Infliximab Induction - Infliximab 5mg/kg at Week 0, Week 2 and Week 6


Treatment: drugs: Infliximab
INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Colectomy free survival</outcome>
      <timepoint>Day 90</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Clinical response - defined as a reduction in the Lichtiger score below 10 with a decrease of at least 3 points</outcome>
      <timepoint>Day 14</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment failure - Absence of clinical response at day 7
Relapse between day 7 and 90 (defined as a Lichtiger score increase of at least 3 points from the previous value that lasts for at least 3 consecutive days and leads to treatment modification)
A severe adverse event leading to treatment interruption
Colectomy by day 90
Death.</outcome>
      <timepoint>Up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Differences in daily Lichtiger score</outcome>
      <timepoint>From day 0 to day 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Steroid free remission - defined as a Mayo disease activity index score =2 with an endoscopic subscore =1</outcome>
      <timepoint>Day 90</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Endoscopic remission rate - defined as a Mayo endoscopic subscore of 0</outcome>
      <timepoint>Day 90</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Endoscopic remission rate - defined as a Mayo endoscopic subscore of 0</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Colectomy free survival</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age &gt;18 years old

          -  Diagnosis of Ulcerative Colitis

          -  Acute Severe Colitis according to the Truelove and Witt's Criteria

          -  Steroid refractory according to the Oxford Criteria</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Participant unable to consent for themselves

          -  Indication for immediate surgery (acute abdomen, perforation of the bowel,
             haemorrhage)

          -  Crohn's disease

          -  Participants with enteric infection confirmed on stool microscopy, culture or toxin

          -  Haemodynamic instability (mean arterial pressure &lt;60) and not responsive to fluids

          -  Participants with clinically significant Cytomegalovirus infection (positive inclusion
             bodies, immunohistochemistry and signs of viraemia such as fever and abnormal liver
             function tests)

          -  Participants who are pregnant or currently breast-feeding

          -  Participants with current malignancy, excluding basal cell carcinoma

          -  Participants with flat low or high grade colonic dysplasia; sporadic adenomas
             permitted

          -  Participants with serious co-morbidities including: Immunodeficiency; Myocardial
             infarction or acute stroke within the last 3 months; Moderate or severe heart failure
             (New York Heart Association class III or IV); Active or suspected tuberculosis; Renal
             failure; Hepatic failure; other severe infections

          -  Participants with history of hypersensitivity to infliximab or infliximab biosimilar

          -  Participants who have received other immunosuppressive agents including but not
             limited to: Anti-TNF therapies within 3 months of screening (Infliximab, Infliximab
             biosimilar, Golimumab, Etanercept, Certolizumab or Adalimumab); Anti-integrins
             (Vedolizumb, Etrolizumab) within 4 months of screening; Calcineurin inhibitors
             (Cyclosporine, Tacrolimus) within 4 weeks of screening; T or B cell depleters
             (Rituximab, Alemtuzumab) within 12 months of screening; other investigational agents
             (eg. Ustekinumab) within 6 months of screening</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>138</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/09/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Austin Health - Melbourne</hospital>
    <postcode>3084 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Austin Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Melbourne</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to identify whether an Accelerated or Intensified Infliximab
      induction regimen is superior to Standard induction in Acute Severe Ulcerative Colitis in an
      open label multi-centre randomised controlled trial.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02770040</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter De Cruz, MBBS PhD FRACP</name>
      <address>Austin Health, Melbourne</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Peter De Cruz, MBBS PhD FRACP</name>
      <address />
      <phone>+61 3 9496 6845</phone>
      <fax />
      <email>Peter.DeCruz@austin.org.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>